Universities Segregate Stem Cell Research

The Bush Administration ban on federal funding for research involving human embryonic stem cell lines created after Aug. 6, 2001 has presented scientists with practical problems, as well as moral and ethical dilemmas. According to the policy, no federal dollars can feed work on new lines of human embryonic stem cells. Such research could hold hope for patients with Alzheimer and Parkinson diseases, diabetes, spinal cord injuries, and other afflictions.Now that private and state funds are arrivin

Written byPeg Brickley
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The Bush Administration ban on federal funding for research involving human embryonic stem cell lines created after Aug. 6, 2001 has presented scientists with practical problems, as well as moral and ethical dilemmas. According to the policy, no federal dollars can feed work on new lines of human embryonic stem cells. Such research could hold hope for patients with Alzheimer and Parkinson diseases, diabetes, spinal cord injuries, and other afflictions.

Now that private and state funds are arriving to fill the gap left by the federal ban, researchers are still faced with a quandary: how to work with new stem cell lines without endangering their access to federal funding.

In California, Massachusetts, Wisconsin, Minnesota, New York, and New Jersey, institutions have or are planning federally funded research on historical stem cells or on those from nonhuman or nonembryonic organisms. Such research would be taking place alongside the development of new ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies